Zhitong Finance App News, Hanson Pharmaceutical (03692) issued an announcement. On October 17, 2026, the company's wholly-owned subsidiaries Shanghai Hanson Biomedical Technology Co., Ltd., Changzhou Hengbang Pharmaceutical Co., Ltd., and Hansoh Bio, LLC (collectively “Hanson”), and F. Hoffmann-La Roche Ltd (Roche) entered into a strategic partnership and licensing agreement.
The strategic cooperation covers a portfolio of antibody-drug conjugate (ADC) projects, including two Hanson preclinical ADC projects, and multiple ADC projects developed using Roche's proposed targets and based on Hanson's own ADC technology platform.
According to the cooperation agreement, Hanson will lead the early development of these projects and complete the global Phase Ia clinical trial at the latest. Roche will be responsible for further development of such projects around the world (excluding mainland China, Hong Kong, Macau, and Taiwan). Hanson reserves all rights in developing, registering and commercializing such projects in mainland China, Hong Kong, Macau, and Taiwan.
Hanson will receive a down payment of US$400 million and a first anniversary payment of US$110 million, and will be eligible to collect milestone payments of potentially over US$15 billion based on the development, registration and commercialization of such projects, as well as tiered royalties based on future potential product sales. According to the cooperation agreement, Hanson has the option to designate up to two projects and participate in their development outside of mainland China, Hong Kong, Macau, and Taiwan, and is eligible to receive additional benefits from the commercialization of these two projects in the US in return for such investment.
F. Hoffmann-La Roche Ltd is a subsidiary of Roche Holding AG listed on the Swiss Stock Exchange. Founded in 1896 in Basel, Switzerland, Roche is now a leading supplier of transformative medicines and diagnostic solutions to millions of people in more than 150 countries around the world.